Please login to the form below
Inlyta
This page shows the latest Inlyta news and features for those working in and with pharma, biotech and healthcare.
Keytruda scores in neoadjuvant triple negative breast cancer combo
Meanwhile, Keytruda is continuing to advance in other indications. In Europe, the Committee for Medicinal Products for Human Use (CHMP) has recommended Keytruda in combination with Inlyta (axitinib) as a
Latest news
-
CHMP backs Bayer’s tumour-agnostic drug Vitrakvi
Merck picked up another positive opinion for Keytruda, this time for use alongside Pfizer’s targeted cancer drug Inlyta (axitinib) for first-line treatment of renal cell carcinoma, and Bristol-Myers
-
Merck bulks up in cancer with $2.2bn Peloton buy
Keytruda is already making waves in RCC, having been approved for first-line RCC alongside Pfizer’s Inlyta (axitinib) in April.
-
Keytruda monotherapy fails in triple negative breast cancer
It added another new indication in April when it gained FDA approval in combination with Pfizer’s Inlyta for kidney cancer patients.
-
Merck claims key FDA okay for Bavencio in kidney cancer
The FDA has just approved Pfizer-partnered Bavencio (avelumab) in combination with Pfizer’s Inlyta (axitinib) as a first-line therapy for patients with advanced renal cell carcinoma (RCC), the most ... However it was pipped to the post in that
-
Bad news for BMS as Keytruda kidney cancer combo approved
Opdivo and Yervoy combination will be squeezed. The FDA has approved Merck’s top-seller Keytruda in combination with Pfizer’s Inlyta for patients with kidney cancer, putting it in direct ... Given the green light well ahead of its expected date, the
More from news
Approximately 6 fully matching, plus 26 partially matching documents found.
Latest Intelligence
-
The handover: Pfizer reshapes itself for a new era
The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it ... The JAVELIN Renal 101 trial combining Bavencio with Inlyta in
-
Cancer immunotherapy: What's on the horizon?
They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Mirna hires former Pfizer director as CMO
Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
A stumble, but not a fall – what’s next for Opdivo?
Back then, the UK’s cost-effectiveness watchdog NICE deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower
-
Oncology drugs under AMNOG
A benefit was found for Inlyta compared with Nexavar in the cytokine treatment group, on the basis of increased tolerability. ... of benefit in one category for these patients was enough to send Inlyta to negotiations for pricing.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Director, Healthcare Communications
-
Salary TBC
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
